Massachusetts Financial Services Co. MA Raises Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Massachusetts Financial Services Co. MA increased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report) by 2.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 688,228 shares of the biopharmaceutical company’s stock after acquiring an additional 15,831 shares during the period. Massachusetts Financial Services Co. MA owned approximately 0.55% of Alnylam Pharmaceuticals worth $121,885,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 1.2% in the first quarter. Vanguard Group Inc. now owns 10,829,144 shares of the biopharmaceutical company’s stock valued at $1,768,291,000 after purchasing an additional 126,373 shares in the last quarter. BlackRock Inc. grew its holdings in Alnylam Pharmaceuticals by 0.7% during the 1st quarter. BlackRock Inc. now owns 8,548,962 shares of the biopharmaceutical company’s stock valued at $1,712,528,000 after buying an additional 59,582 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its position in Alnylam Pharmaceuticals by 0.3% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,202,793 shares of the biopharmaceutical company’s stock worth $761,144,000 after buying an additional 10,609 shares in the last quarter. State Street Corp raised its holdings in shares of Alnylam Pharmaceuticals by 2.1% in the first quarter. State Street Corp now owns 2,909,490 shares of the biopharmaceutical company’s stock worth $475,091,000 after acquiring an additional 59,101 shares during the last quarter. Finally, Capital International Investors lifted its position in shares of Alnylam Pharmaceuticals by 29.2% in the second quarter. Capital International Investors now owns 2,880,643 shares of the biopharmaceutical company’s stock valued at $547,152,000 after acquiring an additional 651,054 shares in the last quarter. Institutional investors and hedge funds own 93.98% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 2.1 %

ALNY stock opened at $168.60 on Thursday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $148.10 and a twelve month high of $227.91. The company has a market capitalization of $21.16 billion, a P/E ratio of -40.72 and a beta of 0.43. The firm has a 50 day simple moving average of $183.74 and a 200-day simple moving average of $179.92.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Michael W. Bonney sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 27th. The stock was sold at an average price of $195.00, for a total transaction of $5,850,000.00. Following the sale, the director now owns 16,029 shares in the company, valued at $3,125,655. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 1.40% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Royal Bank of Canada cut their target price on shares of Alnylam Pharmaceuticals from $235.00 to $230.00 and set an “outperform” rating for the company in a research note on Friday, November 3rd. JPMorgan Chase & Co. upped their price objective on shares of Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the company a “neutral” rating in a research note on Thursday, February 1st. HC Wainwright reaffirmed a “buy” rating and issued a $395.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, December 15th. Oppenheimer downgraded Alnylam Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 11th. Finally, Piper Sandler raised their price objective on Alnylam Pharmaceuticals from $210.00 to $217.00 and gave the stock an “overweight” rating in a report on Thursday, December 14th. Six equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $230.95.

Check Out Our Latest Report on ALNY

About Alnylam Pharmaceuticals

(Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

Featured Articles

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.